Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering the compound and its underlying technology The Company also obtained a ...

SOUTH SAN FRANSCISCO, Calif, April 24, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (CERO), (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next ...

SOUTH SAN FRANSCISCO, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative cellular immunotherapy company seeking to ...

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Julie Feder as Chief Financial Officer. Ms. Feder ...

The segment spotlighted the Baylor-led research recently published in Nature Medicine evaluating autologous Multi-Antigen Targeted T cell therapy in patients with pancreatic ductal adenocarcinoma ...

Syndicate led by new investor, Wellington Management, with other new premier life sciences investors including Foresite Capital, Janus Henderson Investors, Novo Holdings A/S, Paradigm BioCapital, RTW ...

Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s proprietary iPSC ...

SAN DIEGO--(BUSINESS WIRE)--Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an ...

Cell-based therapeutics, using cells as therapeutic agents and/or deliver modalities to fight disease, have substantially evolved since the FDA approval of engineered adoptive T cell transfer to treat ...

Ace Therapeutics announces its preclinical ophthalmic drug development services to help expedite the discovery of ...